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nance versus conversion to Prograf immunoprophylaxis in stable heari transplant recipi- 
ents exhibiting persistent dyslipidemia despite optimal treatment with lipid-lowering 
agents. Methods: One hundred and twenty nine stable heart transplant recipients, aged 
56.7+10.1 years (mean&D) and 77.9i42.2 months post-op. were randomized to con- 
tinue on Neoral (n=64) or switch to Prograf (1x65). Comprehensive lipid profile was mea- 
sured at baseline (bsl)and after I, 3 and 6 months (6 mo). Hemostatic parameters 
(fibrinogen, factor VII. VIII. van Willebrand) and proinflammatory markers (hsCRP, 
homocysteine, slCAM, sVCAM, MCP-I, TPA. PAI-1) were measured at bsl and at 6 mo. 
Results: The Prograf-treated group exhibited a sigmficant greater decrease in total cho- 
lesterol [5.5ltl.l6 (bsl) versus 4.88tl.22 mmol/L. (6 mo): Prograf, versus 5.61+1.36 
(bsl): 5.38iO.87 mmol/L (6 mo): Neoral, p=O.O021]. The Prograf-group also yielded a sig- 
nificant decrease in LDL-cholesterol [3.10+0.8 (bsl) versus 2.72+0.88 mmollL (6 mo); 
p=O.OOS), and cholesterol/HDL ratio 14.73k1.48 (bsl) versus 4.15*1.36 (6 mo) p=O.O17]. 
The decrease in cholesterol was maximum at one month post-switch. For patients 
treated with Prograf. the change in plasma creatinine from baseline to month 6 [mean=- 
6.97t25.291 was significantly greater than for patients who remained on Neoral 
[mean=l.13+19.53] [p=O.O148]. Plasma glucose remains stable in the Prograf-treated 
patients [5.96*1.60 versus 6.01*1.87 mmol/L]. Conclusions: This large prospective con- 
version study showed that Prograf based immunoprophylaxis provides a significant 
decrease in total, LDL-cholesterol and CholesterotlHDL ratio as well as an improvement 
in renal function. These provide a rationale for the use of Prograf in cardiac transplant 
patients with treated but persisting dyslipidemia. 
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Background: Human adipocyte expression and protein levels of TNF-a and TNF recep- 
tor superfamily (TNFRSF) IB are positively correlated with body mass index (BMI) and 
insulin levels, and inversely correlated with adipose tissue lipoprotein lipase activity. In 
this study, we examine the relationships of select inflammatory mediators in the athero- 
genie dyslipoproteinemia (ADL) subjects and the effects of statin therapy on soluble 
TNFRSFs. 
Methods: 60 non-smoking, normoglycemic (HbAlc ~8%) subjects participating in a ran- 
domized 8 week trial comparing statin or placebo. ADL (TG >1.69 mmol/L, HDL-C cl.04 
mmoWL (40 mg/dL) in men and cl.30 mmol/L (50 mg/dL) in women, and/or small LDL 
(40.5 nm) was present in 42 subjects. 
Results: ADL subjects were younger (mean f SD; 49 + 8 YS 54 * 7 y, p=O.O19) and had 
higher levels of both TNF-a (7.9 f 18.1 vs 2.1 * 0.5 ng/mL, p=O.O13) and sTNFRSFlB 
(3.0 * 0.6 vs 2.7 f 0.5 ng/mL, p=O.OSS) compared to the 18 non-ADL subjects. After 
adjustment for age and gender, TNF-n (p=O.O47), sTNFRSFlA (p=O.O50) and 
sTNFRSFlB (p=O.O024) were predictive of ADL. There were no age and gander 
adjusted associations between IL-6 (p=O.O56) or hs-CRP (p=O.O93) and ADL status. Sta- 
tin therapy reduced TNF-a levels more in ADL subjects (7.9 * 18.1 to 6.2 * 11.9 ng/mL, 
p=O.O88) than in non-ADL subjects (2.1 + 0.5 ng/mL to 2.4 * 0.2 ng/mL, p=O.55), 
whereas sTNFRSFlA or sTNFRSFlB levels did not change. 
Conclustons: High levels of TNFa and TNFRSF IA and IB are markers of the proin- 
flammatory state in ADL. 
Predictors of Atherogenic Dyslipoprotenwnra: Multivanate Logistic Regression Analysis 
Overall Classification Overall P-Value 
Accuracy, % for Model 
Age + Gender 67.6 0.022 
Additional adjustment for: 
BMI 65.0 0.084 
TNFa 66.7 0.047 
sTNFRSF1 B 70.0 0.0024 
sTNFRSFlA 61.7 0.050 
IL-6 69.5 0.056 
hs-CRP 66.1 0.093 
sTNFRSFlA + sTNFRSFlB 74.6 0.0038 
sTNFRSF1 B + sTNFRSFlA + basal 66.7 0.047 
TNFa 
sTNFRSF1 B + sTNFRSFlA + IL-6 68.3 0.056 
sTNFRSF1 B + sTNFRSFlA + -hs-CRP 63.3 0.093 
sTNFRSFlA + sTNFRSFlB + TNFa + 66.7 0.037 
IL-6 + hs-CRP 
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Bsckground: Cardiovascular (CV) disease risk factors have been associated with global 
abnormalities in vascular function and structure, as quantified by increased arterial stiff- 
ness. Arterial distensibility decreases with age and the extent of arteriosclerosis. The 
subsequent rise in pulse pressure increases left ventricular work, thereby promoting left 
ventricular hypertrophy, a risk factor for CV morbidity. However, arterrosclerosis may 
affect segments of the vascular tree non-uniformly. The effect of CV risk factors on focal 
areas of the vascular tree is less well studied. Therefore, vascular function in the brachial 
artery and relationships with multiple CV disease risk factors were examined. Methods: 
Brachial artery distensibility was measured using pulse waveform analysis (DynaPulse 
2OOOA Pulse Metric, Inc.) (precision = 0.009543 mmHg-t; coefficrent of variation = 
14.7%; reliability = 0.58). CV risk factors evaluated included serum total and HDL choles- 
terols, serum triglycerides, glucose, body mass Index, and systolic blood pressure. Data 
were collected on 803 young adults from a community-based population (42% male, 
72% white, 19-37 years). Subjects were defined to have an abnormality in risk factor lev- 
els if they ranked in the highest quartile for this population (lowest quartile for HDL). 
Results: Approximately 58% of subjects had elevated levels in one or fewer risk factors, 
18% had clusters of two risk factors, and 24% had clusters of three or more risk factors. 
Results showed distensibility was significantly lower in blacks than in whrtes (0.063 vs. 
0.066 mmHg’ , p<O.M)5). An kwerse linear relationship was found between distensibility 
and the number of risk factors clustering in an individual (pcO.0001 for trend analysis). 
Conclusions: These observations show that clustering of risk factors is assocrated with 
decreased brachial artery distensibility in young adults and non-invasive measures of 
brachial artery funchon are useful in measuring sub-clinical vascular changes related to 
arteriosclerosis. 
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Introduction: LDL apheresis according to HELP (APH) is used to treat severe hypercho- 
lesterolemia in patients (pts.) with coronary artery disease. It has been argued that either 
hyperchobsterobmia or extracorporeal treatment may enhance oxidative stress. Our 
study aimed to investigate the influence of a single APH on plasma concentrations (PC) 
of cholesterol oxidation products, urotensln and relaxin in pts. with heterozygous familiar 
hypercholesterolemia and advanced coronary artery disease enrolled in a chronic weekly 
APH. 
Methods: PC of oxidized LDL (oxLDL), superoxide dismutase (Cu/ZnSOD). relaxin and 
urotensin were determined by ELISA, malondialdehyde (MDA) by HPLC, the antioxida- 
tive serum capacity (ImAnOx) by photometric method. Samples of 12 pts. (6 F, 57 y *IO) 
were collected before (pre), immediately after (postl), and prior to the next APH (post2) 
after a week. 
Results: Pts. wth heterozygous familiar hypercholesterolemia showed higher PC of 
oxLDL than healthy controls (n=30). 11.4+6mU/I vs 7.7 mU/I (~~0.05) proportional to 
LDL-chol. (r=0.8, pcO.0601). APH reduced LDL-chol. and oxLDL by 52% and 45%, 
respectively. MDA declined by 30%. Cu/ZnSOD was not changed. Relaxin and uro- 
tensine decreased significantly. 
Conclusions: Single APH reduces cholesterol oxidation products as well as the vaso- 
constrictor urotensin without having an influence on plasma Cu/ZnSOD. The antioxida- 
tive serum capacity tends to decline after APH. 
Pre post 1 pre vs post 1 post 2 pre vs post 2 
OxLDL (mu/L) 11.4+6 6.25+3 p<o.o1 IO*3 n.s. 
MDA (umolll) 1.27iO.3 0.9+0.14 p<O.Ol 1.25kO.2 “.s 
ImAnOx (pmolll) 317*35 287+46 pzo.03 312*29 “.S. 
CU/ZnSOD (ng/ml) 75+36 71+27 n.s. 64220 no. 
Relaxin (pg/ml) 54+52 42244 p<o.o5 50*43 ns. 
Urotensin @g/ml) 40572983 23182656 p<O.OOOl 3636*1092 “.s. 
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Background: Statins exert benificial effects on the vascular wall beyond cholesterol (C) 
lowering. Changes of these pleiotropic effects after discontinuation of statin remained 
unknown. 
Methods: Fourteen patients (8 F, 6 M, 59+17 years) with hypercholesterolemia were 
enrolled. The following 5 sets of serum liprd and 3 serum markers including vascular cell 
adhesion molecule-l(VCAM-I). 6-isoprostane(lS0) and trssue plasmrnogen activa- 
tor(tPA) for each patient were assessed:(l) at baseline; (2) 12 weeks after atovasta- 
tin(A)(lOmg/day); (3) at day I; (4) at day 2; (5) at day 3 after withdrawal of A. 
